gRNA ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ - Á¦Ç° ¹× ¼­ºñ½ºº°, gRNA À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2024-2030³â)
gRNA Market Size, Share & Trends Analysis Report By Product & Services (Products, Custom gRNA Synthesis Services), By gRNA Type (Research-Use), By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå : 1433539
¸®¼­Ä¡»ç : Grand View Research
¹ßÇàÀÏ : 2024³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 110 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,350,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,753,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,560,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

gRNA ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°è gRNA ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 16¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í, 2024³âºÎÅÍ 2030³â±îÁö º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 18.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Â÷¼¼´ë ½ÃÄö½Ì(NGS)ÀÇ Ã¤¿ëÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ½ÃÀåÀ» Å©°Ô ¹Ð¾î ¿Ã¸®°í ÀÖ½À´Ï´Ù. NGS ±â¼úÀÌ º¸±ÞµÊ¿¡ µû¶ó ¿¬±¸ÀÚ¿Í °úÇÐÀÚ¿¡°Ô °Ô³ð ºÐ¼® ¹× Á¶ÀÛÀ» À§ÇÑ °í±Þ ´É·ÂÀ» Á¦°øÇÕ´Ï´Ù. NGS´Â À¯Àü ¹°ÁúÀÇ ³ôÀº 󸮷® ½ÃÄö½Ì¸¦ °¡´ÉÇÏ°Ô ÇÏ¿© Àüü °Ô³ðÀ» ºü¸£°í ºñ¿ë È¿À²ÀûÀ¸·Î Á¶»çÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ È¿À²¼ºÀº À¯ÀüÀÚ Á¶ÀÛÀÇ Ç¥Àû À¯ÀüÀÚÀÇ È®Àΰú °ËÁõÀ» ¿ëÀÌÇÏ°Ô Çϱ⠶§¹®¿¡ gRNA ¿ëµµ¿¡ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. NGS ±â¼úÀº °Ô³ð ¼­¿­ÀÇ Á¤È®Çϰí Á¾ÇÕÀûÀÎ ÀÌÇØ¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ Á¤¹Ðµµ´Â CRISPR/Cas ½Ã½ºÅÛÀ» ÀÌ¿ëÇÑ À¯ÀüÀÚ ÆíÁý °úÁ¤¿¡¼­ À¯ÀüÀÚÀÇ Á¤È®ÇÑ Å¸°ÙÆÃÀ» º¸ÀåÇÏ´Â ³ôÀº ƯÀ̼ºÀ» °¡Áø gRNAÀÇ ¼³°è¿¡ ÇʼöÀûÀÔ´Ï´Ù.

°Ô´Ù°¡ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷°ú Á¦¾à ±â¾÷¿¡ ÀÇÇÑ R&D Ȱµ¿¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡´Â ÇâÈÄ ¼ö³â°£ ½ÃÀå Ȱ¼ºÈ­·Î À̾îÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. »ç¿ëÀÚ Ä£È­ÀûÀ̰í Àú·ÅÇÑ gRNA ÇÕ¼º ŰƮ¿Í ¼­ºñ½º°¡ °³¹ßµÊ¿¡ µû¶ó CRISPR-Cas9 ±â¼úÀº ¸ðµç ¼öÁØÀÇ ¿¬±¸ÀÚ¿¡°Ô ´õ Ä£¼÷ÇØÁ³½À´Ï´Ù. CRISPR-Cas9ÀÇ »õ·Î¿î ¿ëµµÀÇ Áö¼ÓÀûÀÎ ¹ß°ßÀº gRNA ¼ö¿ä¸¦ ºÎÃß±é´Ï´Ù.

¶ÇÇÑ, »õ·Î¿î gRNA ÃÖÁ¾ Á¦Ç°ÀÇ Ãâ½Ã´Â ±â¼ú Çõ½ÅÀ» ÃËÁøÇϰí, ±â¾÷ ½ÃÀå µµ´Þ ¹üÀ§¸¦ È®´ëÇϰí, À¯ÀüÀÚ ÆíÁý ±â¼úÀÇ Ã¤ÅÃÀ» °¡¼ÓÈ­Çϰí, Àüü ½ÃÀåÀÇ ¼ºÀå°ú Áøº¸¿¡ ±â¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î(2023³â) 10¿ù, °Ô³ð °øÇÐ ¼Ö·ç¼ÇÀÇ À¯¸íÇÑ °ø±ÞÀÚÀÎ Synthego´Â IND-enabling(INDe) gRNA¸¦ Ãâ½ÃÇß½À´Ï´Ù. ÀÌ Çõ½ÅÀûÀÎ Á¦°øÀº CRISPR ±â¹Ý ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·áÀÇ ÀüÀÓ»ó ÆÄÀÌÇÁ¶óÀο¡¼­ Áß¿äÇÑ Áøº¸¸¦ ÀǹÌÇÕ´Ï´Ù. ÀÌ Á¦Ç°Àº GLP ±ÔÁ¦ÀÇ ÀüÀÓ»ó½ÃÇè ¹× IND-enabling ½ÃÇèÀ» À§ÇØ ¸é¹ÐÈ÷ ¼³°èµÈ °íǰÁúÀÇ gRNA¸¦ ¿¬±¸ÀÚ¿¡°Ô Á¦°øÇÔÀ¸·Î½á ¼³°è ¹× Á¦Á¶ Àü¹Ý¿¡ °ÉÃÄ Á¾ÇÕÀûÀÎ IND¿¡ ÁذÅÇÑ Àç·á¿Í ¹®¼­¸¦ Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µË´Ï´Ù.

gRNA ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå gRNA ½ÃÀå : ÁÖ¿ä ¿ä¾à

Á¦3Àå gRNA ½ÃÀå º¯¼ö, µ¿Çâ ¹× ¹üÀ§

Á¦4Àå Á¦Ç°°ú ¼­ºñ½ºÀÇ ÃßÁ¤,µ¿Ç⠺м®

Á¦5Àå gRNA À¯ÇüÀÇ ÃßÁ¤,µ¿Ç⠺м®

Á¦6Àå ¿ëµµÀÇ ÃßÁ¤,µ¿Ç⠺м®

Á¦7Àå ÃÖÁ¾ ¿ëµµÀÇ ÃßÁ¤,µ¿Ç⠺м®

Á¦8Àå Áö¿ª ºñÁî´Ï½º ºÐ¼®

Á¦9Àå °æÀï ±¸µµ

BJH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

gRNA Market Growth & Trends:

The global gRNA market size is anticipated to reach USD 1.62 billion by 2030 and it is projected to grow at a CAGR of 18.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising adoption of Next-Generation Sequencing (NGS) is significantly boosting the market. As NGS technologies become more prevalent, they empower researchers and scientists with advanced capabilities for genomic analysis and manipulation. NGS enables high-throughput sequencing of genetic material, allowing for the rapid and cost-effective examination of entire genomes. This efficiency is crucial for gRNA applications, as it facilitates the identification and validation of target genes for genetic manipulation. NGS technologies provide a precise and comprehensive understanding of genomic sequences. This precision is vital for designing gRNAs with high specificity, ensuring accurate targeting of genes during the gene editing process using CRISPR/Cas systems.

Furthermore, the increasing investments by biotechnology and pharmaceutical companies for R&D activities are expected to fuel the market in the coming years. The development of user-friendly and affordable gRNA synthesis kits and services has made CRISPR-Cas9 technology more accessible to researchers of all levels. The continuous discovery of novel applications for CRISPR-Cas9 fuels the demand for gRNA.

Additionally, the launch of new gRNA final products can drive innovation, expand the market reach of players, and accelerate the adoption of gene editing technologies, contributing to the overall growth & advancement of the market. For instance, in October 2023, Synthego, a prominent provider of genome engineering solutions, launched IND-enabling (INDe) gRNAs. This transformative offering marks a significant advancement in the CRISPR-based cell and gene therapy preclinical pipeline. By providing researchers with high-quality gRNAs meticulously designed for GLP-regulated preclinical and IND-enabling studies, this product incorporates comprehensive IND-compliant materials and documentation throughout its design and production. Thus, it will drive the market growth.

gRNA Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. gRNA Market: Executive Summary

Chapter 3. gRNA Market Variables, Trends, & Scope

Chapter 4. Product & Services Estimates & Trend Analysis

Chapter 5. gRNA Type Estimates & Trend Analysis

Chapter 6. Application Estimates & Trend Analysis

Chapter 7. End-Use Estimates & Trend Analysis

Chapter 8. Regional Business Analysis

Chapter 9. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â